Miraculins diagnostic news

Miraculin’s board began a strategic review and will consider various strategic alternatives, including a revised business plan, a merger, sale or strategic license of all or part of its assets. The company said the review is a result of the “current share price and difficulty accessing the required capital to fully execute on the Company’s current business plan.” ...